The company has not filed an annual or quarterly report since its FY2018 10-K, filed Mar 13, 2019. Its latest SEC filing is a 15-12B from Apr 12, 2019.
10-K for FY2018, filed Mar 13, 2019
The sections below describe the company as of the FY2018 annual report.
Develops immunotherapy drug candidates for cancer patients and licenses vaccine technology to pharmaceutical companies for infectious and allergic diseases.
10-K for FY2018, filed Mar 13, 2019We are a clinical-stage immunotherapy company employing next-generation, diversified in vivo approaches designed to enable the body’s…View ↗
Selectively monetize non-oncology indications, while retaining optionality for future internal development. ZVex and GLAAS also have…View ↗
Although immuno-oncology development is robust with therapies for an estimated 10 liquid and 18 solid tumors in development and with a…View ↗
Partners pay upfront license fees, milestone payments tied to development, regulatory or commercial progress, and royalties on licensed-product sales; GLA customers pay for product when it ships.
10-K for FY2018, filed Mar 13, 2019We enter into collaboration and out-licensing agreements which are within the scope of Topic 606, under which we perform research and…View ↗
Milestone payments. At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones…View ↗
Royalties. Arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is…View ↗
Revenue from product sales of glucopyranosyl lipid A (GLA), a product from our GLAAS platforms, is recognized when the Customer obtains…View ↗
$2.2M
10-K for FY2018, filed Mar 13, 2019
$2.2M ↗
Pharmaceutical companies license platform rights and collaborate on development; customers also buy GLA products.
10-K for FY2018, filed Mar 13, 2019Selectively monetize non-oncology indications, while retaining optionality for future internal development. ZVex and GLAAS also have…View ↗
We have a preclinical vaccine product candidate called G103 to treat herpes simplex virus type 2, or HSV2. G103 consists of several…View ↗
We enter into collaboration and out-licensing agreements which are within the scope of Topic 606, under which we perform research and…View ↗
Revenue from product sales of glucopyranosyl lipid A (GLA), a product from our GLAAS platforms, is recognized when the Customer obtains…View ↗
10-K for FY2018, filed Mar 13, 2019
We consider significant revenue concentrations to be customers who account for 10% or more of total revenues generated by us during the…View ↗
No. It lost $54.8M in .
10-K for FY2018, filed Mar 13, 2019
8-K, filed Apr 2, 2019
As previously disclosed, on February 20, 2019, Immune Design Corp., a Delaware corporation (the “Company”), entered into an Agreement and…View ↗
Shrank. Revenue fell 66% in 4 years, from $6.4M in to $2.2M in , about 24% a year.
Focused oncology development
The earlier report described distinct oncology candidates from both discovery platforms; the later report centers oncology development on its lead candidate and pauses other platform programs, while seeking outside collaborators for a cancer vaccine program.
10-K for FY2015, filed Mar 15, 2016 10-K for FY2018, filed Mar 13, 2019We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight…View ↗
Loading...
